Navigation Links
Ustekinumab Phase 3 data show long-term improvement of chronic plaque psoriasis
Date:2/2/2008

SAN ANTONIO, TX, February 2, 2008 One-year data from a second double-blind, placebo-controlled Phase 3 study showed therapy with ustekinumab given every 12 weeks provided sustained, clinically meaningful improvement in the treatment of moderate to severe plaque psoriasis through one year. According to findings presented at the Annual Meeting of the American Academy of Dermatology, 87 percent of patients responding to ustekinumab 45 mg maintenance therapy and 91 percent of patients responding to ustekinumab 90 mg maintenance therapy sustained at least a 75 percent improvement in psoriasis through one year, as measured by the Psoriasis Area and Severity Index (PASI 75). Ustekinumab is a new human monoclonal antibody with a novel mechanism of action that targets the cytokines interleukin-12 (IL-12) and interleukin-23 (IL-23), naturally occurring proteins that are important in the bodys regulation of immune responses and that are also believed to play a role in immune-mediated inflammatory disorders, including psoriasis.

In December 2007, Centocor announced that a Biologics License Application (BLA) had been submitted to the U.S. Food and Drug Administration (FDA) and Janssen-Cilag International NV announced its submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMEA).

These findings show that ustekinumab may control plaque psoriasis with as few as four injections a year, says lead study investigator Kenneth Gordon, MD, associate professor, Feinberg School of Medicine, Northwestern University, and Head of Dermatology, Evanston Northwestern Healthcare, Skokie, IL. We are encouraged by the results seen in clinical trials to date and the hope that ustekinumab may hold for patients and the dermatology community.

The primary endpoint of the Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Safety of CNTO 1275 in the Treatment of Subjects with Mode
'/>"/>

Contact: Brian Kenney
BKenney1@cntus.jnj.com
215-325-2107
Centocor, Inc.
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. Medarex to Receive Milestone Payment for Submission of Regulatory Applications Requesting Approval of Ustekinumab (CNTO 1275) for Treatment of Psoriasis
2. Promising Phase 3 trial results show biologic therapy ustekinumab significantly improved psoriasis
3. Kiadis Pharma Announces Successful Completion of Rhitol(TM) Phase II Clinical Study
4. Medivation Plans to Initiate Pivotal Confirmatory Phase 3 Trial of Dimebon(TM) for Alzheimers Disease in Second Quarter of 2008
5. MDS Pharma Services Opens Largest Phase I Clinic on U.S. West Coast
6. Immunosyn Announces the Successful Completion of First Phase Proof of Concept Trial in Europe for Treatment of Diabetic Ulcers With Biopharmeceutical SF-1019
7. MAP Pharmaceuticals Reaches Agreement with FDA on Special Protocol Assessment for MAP0004 Phase 3 Clinical Trial in Patients With Migraine
8. Bisexuality not a transitional phase among women, according to new research
9. Cadence Pharmaceuticals Announces Topline Results of Two Phase III Clinical Trials of Acetavance(TM)
10. Kosan Opens TIME-1 Pivotal Phase 3 Trial in Multiple Myeloma
11. Ardea Biosciences Lead NNRTI for HIV, RDEA806, to Enter Phase 2a Proof-of- Concept Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... York, New York (PRWEB) December 24, 2014 ... ( http://www.xareltolawsuit2015.com/ ) that allege the blood thinner ... complications has outlined a leadership structure for the ... Order dated December 17th, the Court plans to ... the parties and also plans on appointing a ...
(Date:12/24/2014)... The report “Stivarga (Colorectal Cancer) – ... current treatment landscape, unmet needs, current pipeline and commercial ... drug which is used in the treatment of colon ... is also prescribed to patients who suffer from advanced ... is a multi-kinase inhibitor and it blocks many enzymes ...
(Date:12/24/2014)... By Dennis Thompson HealthDay ... and bisexual men who have abstained from sex for one year ... a new federal policy that would reverse a 31-year ban on ... Food and Drug Administration announced Tuesday its intention to release a ... door to blood donations from gay men. The FDA is ...
(Date:12/24/2014)... WEDNESDAY, Dec. 24, 2014 (HealthDay News) -- A new, ... Food and Drug Administration. The agency on Tuesday ... for those who are overweight and have at least ... type 2 diabetes or high cholesterol. Patients taking ... a low-calorie diet and exercise regularly, the FDA noted. ...
(Date:12/24/2014)... Tara Haelle HealthDay ... -- Teens are more likely to start smoking or ... hyperactivity disorder (ADHD) or conduct disorder, new research ... families about the risk of substance use as [these] ... research director at Cincinnati Pediatric Research Group, which is ...
Breaking Medicine News(10 mins):Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 3Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:FDA to Lift Ban on Blood Donations by Gay Men 2Health News:FDA to Lift Ban on Blood Donations by Gay Men 3Health News:FDA Approves New Weight-Loss Drug 2Health News:FDA Approves New Weight-Loss Drug 3Health News:ADHD May Raise Teens' Odds for Smoking, Drinking 2Health News:ADHD May Raise Teens' Odds for Smoking, Drinking 3
... Ann Karmanos Cancer Institute and Karmanos Cancer Center ... Ann G. Schwartz, Ph.D. has been appointed Interim ... has been appointed Interim Chief Operating Officer.(Logo: ... to lead us during this period of transition," ...
... 5 Change to Win chair Anna ... House Forum on Health Reform, which was attended by various ... as a nation that are as complex and consequential as ... their health coverage every day, we can no longer turn ...
... The Pennsylvania Breast Cancer Coalition and the Pennsylvania Association of ... sign up for the 2nd annual Home Run Derby EPHRATA, ... out your baseball bat and head out to the ballpark! ... of Community Bankers have joined together once again to bring ...
... International, LLC officially kicks off "Sleep Better America," ... campaign, with the launch of http://www.sleepbetteramerica.net . ... consumers about sleep-related issues with timely information, tools, ... studies.The "Sleep Better America" Web site centralizes unique ...
... The medication patches should be removed ahead of time, ... The U.S. Food and Drug Administration warned Thursday that ... while patients undergo an MRI. , Thursday,s warning applies ... over-the-counter -- including nicotine and pain-control patches. , Some ...
... suggests that the standard treatment for a common brain ... leaving patients more vulnerable to tumor recurrence. The research, ... of the journal Cell Stem Cell , provides ... stem-like cells to escape cytotoxic treatment and repopulate the ...
Cached Medicine News:Health News:Karmanos Cancer Institute Announces Interim Leadership 2Health News:Karmanos Cancer Institute Announces Interim Leadership 3Health News:Change to Win Statement on White House Health Care Forum 2Health News:Take A Swing Against Breast Cancer! 2Health News:AmericInn Hotels Kicks-Off 'Sleep Better America' With Launch of New Web Site to Educate Consumers About Insomnia and Sleep-Related Issues 2Health News:Skin Patches Can Cause Burns During MRIs 2Health News:Brain tumor treatment may increase number of cancer stem-like cells 2
(Date:12/24/2014)... PRINCETON, N.J. , Dec. 24, 2014 /PRNewswire/ ... Company), a late-stage biopharmaceutical company developing products that ... inflammation, oncology and biodefense, announced today that on ... registered public offering. The Company raised ... offering and intends to use the net proceeds ...
(Date:12/24/2014)... 24, 2014  Diplomat Pharmacy, Inc. (NYSE: ... proud to announce Jennifer Hagerman , Pharm.D., AE-C, ... take office as the president of the Michigan Pharmacists ... will take place Feb. 28, 2015, at the MPA ... the Renaissance Center in Detroit, Michigan ...
(Date:12/24/2014)... SCHOFIELD, Wis. , Dec. 23, 2014 ... and marketer of over-the-counter (OTC) medicinal and healthcare products, ... production of MigraPure® H, a hemp-based, advanced headache relief ... marijuana dispensaries in Colorado , ... . With the MigraPure H Advanced ...
Breaking Medicine Technology:Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 2Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 3PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 3
... Tolerability and,Additive Antiviral Activity of HCV-796 -, EXTON, ... announced additional data from a Phase 1b study,of ... virus (HCV),polymerase inhibitor at the 42nd Annual Meeting ... Liver (EASL). This meeting is,being held in Barcelona, ...
... Data on Innovative Oncology Compounds at the,American ... PARK, Ill., April 13, 2007 /PRNewswire-FirstCall/ -- ... that target,cancer. Researchers now know that cancer ... new blood vessels to deliver oxygen,and nutrients ...
Cached Medicine Technology:ViroPharma Announces Presentation of Additional HCV-796 Data at,Meeting of The European Association for the Study of the Liver 2ViroPharma Announces Presentation of Additional HCV-796 Data at,Meeting of The European Association for the Study of the Liver 3ViroPharma Announces Presentation of Additional HCV-796 Data at,Meeting of The European Association for the Study of the Liver 4ViroPharma Announces Presentation of Additional HCV-796 Data at,Meeting of The European Association for the Study of the Liver 5ViroPharma Announces Presentation of Additional HCV-796 Data at,Meeting of The European Association for the Study of the Liver 6Abbott Researchers Focus on New Cutting-Edge Approaches in the,Fight Against Cancer 2Abbott Researchers Focus on New Cutting-Edge Approaches in the,Fight Against Cancer 3Abbott Researchers Focus on New Cutting-Edge Approaches in the,Fight Against Cancer 4
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: